All In Biotech

Drug Trial Radar · NCT00307502

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Cross-sectional Study for the Characterisation of the Pharmacokinetic Parameters of Protease Inhibitors and Non-nucleoside Analog Reverse Transcriptase Inhibitors in the Spanish Population of HIV-infected Subjects

Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

675

Actual

Start

Jan 2005

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Lead sponsor
Germans Trias i Pujol HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
First posted
Mar 28, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterise the pharmacokinetic profiles of non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), and the influence of the individual characteristics on the pharmacokinetic parameters in the Spanish population of HIV-infected subjects.

Conditions

  • HIV Infections

Interventions

  • NevirapineDrug

    tablets 200 mg, 400 mg/day

  • EfavirenzDrug

    tablets 600 mg, 600 mg/day

  • Indinavir/ritonavirDrug

    Indinavir: capsules 400 mg, 1600 mg/day Ritonavir: capsules 100 mg, 200 mg/day

  • NelfinavirDrug

    tablets 250 mg, 2500 mg/day

  • Saquinavir/ritonavirDrug

    Saquinavir: tablets 500 mg, 2000 mg/day Ritonavir: tablets 100 mg, 200 mg/day

  • Lopinavir/ritonavirDrug

    tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day

  • AtazanavirDrug

    capsules 200 mg, 400 mg/day

  • Atazanavir/ritonavirDrug

    Atazanavir: capsules 150 mg, 300 mg/day Ritonavir: capsules 100 mg, 200 mg/day

  • Fos-amprenavir/ritonavirDrug

    Fos-amprenavir: capsules 700 mg, 1400 mg/day Ritonavir: capsules 100 mg, 200 mg/day

  • Tipranavir/ ritonavirDrug

    Tipranavir: tablets 250 mg, 1000 mg/day Ritonavir: capsules 100 mg, 400 mg/day

  • Darunavir/ritonavirDrug

    Darunavir: tablets 300 mg, 1200 mg/day Ritonavir: capsules 100 mg, 200 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint is the plasma concentration of the PI/NNRTI drugs (Ka absorption constant, CI: plasma clearance, Vd: volume of distribution).Time frame: In the 12 hour (h) pharmacokinetic curve

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Germans Trias i Pujol Hospital

    Badalona, Barcelona, Spain

  • Hospital de Figueres

    Figueras, Barcelona, Spain

  • Fundació Hospital-Asil de Granollers

    Granollers, Barcelona, Spain

  • Hospital de Vic

    Vic, Barcelona, Spain

  • Hospital Universitari Sant Joan de Reus

    Reus, Tarragona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.